Difference between revisions of "Heparin-induced thrombocytopenia"
Jump to navigation
Jump to search
Tag: visualeditor |
Tag: visualeditor |
||
Line 64: | Line 64: | ||
|Fondaparinux | |Fondaparinux | ||
|Similar efficacy and safety to fondaparinux | |Similar efficacy and safety to fondaparinux | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
|} | |} | ||
Line 92: | Line 82: | ||
|Argatroban, Danaparoid | |Argatroban, Danaparoid | ||
|Similar efficacy and safety to argatroban, danaparoid | |Similar efficacy and safety to argatroban, danaparoid | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
|} | |} | ||
Line 120: | Line 100: | ||
|Argatroban | |Argatroban | ||
|Suggests less bleeding in surgical patients with argatroban. | |Suggests less bleeding in surgical patients with argatroban. | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
|} | |} | ||
Revision as of 02:46, 10 September 2018
Section editors | |||
---|---|---|---|
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
Benjamin Tillman, MD Nashville, TN |
0 regimens on this page
0 variants on this page
|
Guidelines
To be completed
All lines of therapy
Argatroban monotherapy
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Lewis et al. 2001 (ARG-911) | Prospective, historical control | Multiple | Reduced all-cause death, all-cause amputation, and new thrombosis |
Treschan et al. 2014 (ALicia) | Randomized, double-blind | Lepirudin | Suggests less bleeding in surgical patients with argatroban. |
Kang M et al. 2015 | Retrospective, propensity score-matched | Fondaparinux | Similar efficacy and safety to fondaparinux |
Anticoagulation
- ARG-911: Argatroban (Acova) 2 mcg/kg/min IV adjusted to maintain activated partial thromboplastin time 1.5 to 3.0 times baseline value.
- ALicia: Argatroban (Acova) without liver dysfunction: 0.5 mcg/kg/min IV adjusted to maintain activated partial thromboplastin time 1.5 to 2.0 times baseline value.
- ALicia: Argatroban (Acova) with severe liver dysfunction (bilirubin >4 mg/dL): 0.25 mcg/kg/min IV adjusted to maintain activated partial thromboplastin time 1.5 to 2.0 times baseline value.
References
- ARG-911: Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG; ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001 Apr 10;103(14):1838-43. link to original article. PubMed.anja A Treschan[author],
- ALicia: Treschan TA, Schaefer MS, Geib J, Bahlmann A, Brezina, T, Werner P, Golla, E, Greinacher A, Pannen B, Kindgen-Milles D, Kienbaum P, Beiderlinden M. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial. Critical Care. 2014 Oct 25;18(5):588. link to original article. PubMed.
- Only 15 patients (23%) in the study had confirmed HIT.
- Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood 2015 Feb 5;125(6):924-9. Link to original article. PubMed.
Danaparoid monotherapy
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Kang M et al. 2015 | Retrospective, propensity score-matched | Fondaparinux | Similar efficacy and safety to fondaparinux |
References
- Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood 2015 Feb 5;125(6):924-9. Link to original article. PubMed.
Fondaprinux monotherapy
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Kang M et al. 2015 | Retrospective, propensity score-matched | Argatroban, Danaparoid | Similar efficacy and safety to argatroban, danaparoid |
References
- Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood 2015 Feb 5;125(6):924-9. Link to original article. PubMed.
Lepirudin monotherapy
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Treschan et al. 2014 (ALicia) | Randomized, double-blind | Argatroban | Suggests less bleeding in surgical patients with argatroban. |
Anticoagulation
- ALicia: Lepirudin paitents with continuous renal replacement therapy: 5 mcg/kg/hr IV adjusted to maintain activated partial thromboplastin time 1.5 to 2.0 times baseline value.
- ALicia: Lepirudin paitents with moderate renal impairment (creatinine >=1.3 mg/dl): 10 mcg/kg/hr IV adjusted to maintain activated partial thromboplastin time 1.5 to 2.0 times baseline value.
- ALicia: Lepirudin paitents with without renal impairment (creatinine <1.3 mg/dl): 50 mcg/kg/hr IV adjusted to maintain activated partial thromboplastin time 1.5 to 2.0 times baseline value.
References
- ALicia: Treschan TA, Schaefer MS, Geib J, Bahlmann A, Brezina, T, Werner P, Golla, E, Greinacher A, Pannen B, Kindgen-Milles D, Kienbaum P, Beiderlinden M. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial. Critical Care. 2014 Oct 25;18(5):588. link to original article. PubMed.
- Only 15 patients (23%) in the study had confirmed HIT.